Lafayette, CA, United States of America

William Usinger


 

 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2008-2020

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations by William Usinger: A Pioneer in Influenza Research

Introduction

William Usinger, based in Lafayette, California, is a distinguished inventor renowned for his contributions to influenza research. With a portfolio of nine patents, Usinger has significantly impacted the field of immunization, particularly with his work on monoclonal antibodies.

Latest Patents

Among his latest innovations, William Usinger has developed monoclonal antibodies that are instrumental in passive influenza immunization. These antibodies and their fragments are designed to be cross-reactive with multiple clades of the influenza virus, including representatives from both Group 1 and Group 2. This groundbreaking research is aimed at controlling influenza epidemics and pandemics, while also providing both prophylactic and therapeutic protection against seasonal influenza. His innovative approach not only enhances our understanding of influenza but also addresses public health challenges associated with viral outbreaks.

Career Highlights

Usinger’s career has included significant roles at reputable companies such as Trellis Bioscience, Inc. and Fibrogen, Inc. His expertise and dedication to advancing medical science have been evident through his substantial contributions to influenza immunization technologies.

Collaborations

Throughout his career, William Usinger has collaborated with esteemed colleagues, including Lawrence M. Kauvar and Stote Ellsworth. These partnerships have facilitated the development and refinement of his innovative antibody therapies, fostering a collaborative environment that promotes scientific discovery.

Conclusion

William Usinger continues to be a pivotal figure in the realm of influenza research, utilizing his extensive knowledge and patent portfolio to drive innovation in public health. His groundbreaking work on monoclonal antibodies not only highlights his inventiveness but also embodies a commitment to addressing global health challenges associated with influenza viruses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…